Reviewing Aevi Genomic Medicine (GNMX) and Its Peers
Aevi Genomic Medicine (NASDAQ: GNMX) is one of 95 public companies in the “Biotechnology” industry, but how does it weigh in compared to its rivals? We will compare Aevi Genomic Medicine to related companies based on the strength of its earnings, risk, valuation, analyst recommendations, institutional ownership, profitability and dividends.
This table compares Aevi Genomic Medicine and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Aevi Genomic Medicine||N/A||-125.94%||-106.93%|
|Aevi Genomic Medicine Competitors||-910.58%||-183.99%||-27.07%|
This is a breakdown of current ratings and price targets for Aevi Genomic Medicine and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Aevi Genomic Medicine||0||1||1||0||2.50|
|Aevi Genomic Medicine Competitors||122||463||1155||11||2.60|
Aevi Genomic Medicine currently has a consensus target price of $4.25, suggesting a potential upside of 221.97%. As a group, “Biotechnology” companies have a potential upside of 54.93%. Given Aevi Genomic Medicine’s higher probable upside, analysts plainly believe Aevi Genomic Medicine is more favorable than its rivals.
Risk and Volatility
Aevi Genomic Medicine has a beta of 0.55, meaning that its share price is 45% less volatile than the S&P 500. Comparatively, Aevi Genomic Medicine’s rivals have a beta of 1.13, meaning that their average share price is 13% more volatile than the S&P 500.
Institutional and Insider Ownership
20.8% of Aevi Genomic Medicine shares are held by institutional investors. Comparatively, 20.4% of shares of all “Biotechnology” companies are held by institutional investors. 15.2% of Aevi Genomic Medicine shares are held by insiders. Comparatively, 19.6% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Valuation and Earnings
This table compares Aevi Genomic Medicine and its rivals top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Aevi Genomic Medicine||N/A||-$37.80 million||-1.29|
|Aevi Genomic Medicine Competitors||$224.52 million||$58.08 million||-1.08|
Aevi Genomic Medicine’s rivals have higher revenue and earnings than Aevi Genomic Medicine. Aevi Genomic Medicine is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Aevi Genomic Medicine rivals beat Aevi Genomic Medicine on 8 of the 12 factors compared.
Aevi Genomic Medicine Company Profile
Aevi Genomic Medicine, Inc., a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. Its lead product candidates include AEVI-001, a glutamatergic neuromodulator, which is in Phase II/III SAGA trial for a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients with specific mutations in their metabotropic glutamate receptor gene network; and AEVI-002, an anti-light monoclonal antibody that is in Phase I clinical trial for use in severe pediatric onset crohns disease. The company was formerly known as Medgenics, Inc. and changed its name to Aevi Genomic Medicine, Inc. in December 2016. Aevi Genomic Medicine, Inc. was founded in 2000 and is based in Wayne, Pennsylvania.
Receive News & Ratings for Aevi Genomic Medicine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aevi Genomic Medicine Inc. and related companies with MarketBeat.com's FREE daily email newsletter.